HR and breast cancer: In conclusion, leuprorelin (Boennuokang®) combined with endocrine therapy effectively suppresses gonadotropins and E2 to postmenopausal levels and demonstrates encouraging long-term PFS rates with a favorable safety profile in premenopausal women with HR+/HER2− breast cancer.